Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequately Controlled, Moderate to Severe, Chronic Low Back Pain.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2016
Price :
$35
*
At a glance
- Drugs Fulranumab (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 18 Apr 2016 Primary endpoint has not been met (Change from baseline in the average low back pain-related pain intensity score) according to the results published in the Clinical Therapeutics.
- 18 Apr 2016 Results published in the Clinical Therapeutics
- 10 Apr 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.